|
Meta analysis of efficacy and safety of FOLFOX regimen and XELOX regimen in patients with advanced colon cancer
CHEN Jinbao, QIU Yanyan, XU Ke, HE Xue, WU Honglei, ZENG Yijun, YIN Peihao
2019, 8 (2):
73-83.
doi: 10.3969/j.issn.2095-378X.2019.02.001
Objective To evaluate the efficacy and safety of FOLFOX regimen and XELOX regimen in the treatment of advanced colon cancer.Methods The following five databases were searched: VIP Database, Chinese BioMedical Literature Database (CBM), China National Knowledge Infrastructure (CNKI), Wanfang Data, and PubMed.The quality assessment and meta analysis of the clinical studies meeting the inclusion criteria were performed using RevMan 5.3 software.Results A total of 12 articles were included in the study, with 1 614 colon cancer patients, 801 to the FOLFOX group and 813 to the XELOX group.There was no significant difference in overall response, complete response, partial response, overall survival, and progression-free survival between the two regimens.The incidence rate of grade Ⅲ/Ⅳ hand-foot syndrome caused by XELOX regimen (RR=0.2, 95% CI 0.08-0.51, P<0.001) was higher than that by FOLFOX regimen, while the grade Ⅲ/Ⅳ neutropenia caused by FOLFOX regimen (RR=5.47, 95%CI 3.42-8.76, P<0.001) was higher than that by XELOX regimen.Conclusion The efficacy of FOLFOX regimen on advanced colon cancer is similar to that of XELOX regimen, but it is worth noting that the risk of grade Ⅲ/Ⅳ hand-foot syndrome caused by XELOX regimen is higher, while the risk of grade Ⅲ/Ⅳ neutropenia caused by FOLFOX regimen is higher.
References |
Related Articles |
Metrics
|